SIREN : 853012508
FF PHARMA is a French company founded 6 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in CHAMPIGNY-EN-BEAUCE (41330), this company of category PME shows in 2024 a revenue of 84 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 84 000 € | 84 000 € | 82 000 € | 78 000 € | 78 000 € | 26 000 € |
| Net income | 13 866 € | 19 935 € | 7 903 € | 5 976 € | 7 830 € | 3 275 € |
| EBITDA | 12 416 € | 8 762 € | 10 295 € | 8 138 € | 10 427 € | 4 322 € |
| Net margin | 16.5% | 23.7% | 9.6% | 7.7% | 10.0% | 12.6% |
In 2024, FF PHARMA achieves revenue of 84 k€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +26.4%. Slight decline of 0% vs 2023. After deducting consumption (0 €), gross margin stands at 84 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 12 k€, representing 14.8% of revenue. Positive scissor effect: EBITDA margin improves by +4.3 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 14 k€, i.e. 16.5% of revenue. This profit can be retained or distributed to shareholders.
84 000 €
84 000 €
12 416 €
12 416 €
13 866 €
14.8%
The debt ratio (= Financial debt / Equity x 100) stands at 54%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.9 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 16.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
53.847%
33.636%
16.507%
4.9
In 2024, the debt ratio of FF PHARMA (53.85) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of FF PHARMA (33.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of FF PHARMA (4.90) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 75.97. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.2x. Operating income very largely covers interest expenses: high safety margin.
75.975
6.234
In 2024, the liquidity ratio of FF PHARMA (75.97) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of FF PHARMA (6.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 255 days. Excellent situation: suppliers finance 255 days of the operating cycle (retail model). WCR is negative (-39 days): operations structurally generate cash. Notable WCR improvement over the period (-653%), freeing up cash.
-9 098 €
0 j
255 j
0 j
-39 j
Indicative estimate only : the number of comparable transactions in this sector is limited (26 transactions). This range of 52 309€ to 148 684€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 26 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FF PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of FF PHARMA in 2024 is 84 k€.
Yes, FF PHARMA generated a net profit of 14 k€ in 2024.
The headquarters of FF PHARMA is located in CHAMPIGNY-EN-BEAUCE (41330), in the department Loir-et-Cher.
The tax return of FF PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FF PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.